Registry update — unassessed
The Safety and Effectivness of Quercetin and Dasatinib on the Epigenetic Aging Rates in Healthy Individuals
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
OBSERVATIONALRoutine significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Aug 3, 2021 · Discovered: Sep 16, 2026 · Assessed: — · Historical research backfill
What it does not prove
- Observational design cannot establish that quercetin and dasatinib caused any changes in epigenetic aging, only whether they co-occurred
- No sample size, effect sizes, or statistical significance reported, so the magnitude and reliability of any findings are unknown
- No control group mentioned, so changes cannot be distinguished from natural variation or placebo effects
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Observational
- Sample size
- —
- Duration
- 4 months
- Population
- Healthy individuals
- Primary outcome
- Epigenetic biological aging rates
- Effect size
- —
- Significance
- Not reported
- Journal
- TruDiagnostic
- Published
- Aug 3, 2021
Sources
Primary source
- TruDiagnostic ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Assessing the effects of Quercitin and Dasatinib over a 16 week period on participatns' epigenetic biological aging. The patients are being tested at baseline, halfway point, and after the trial period.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.